DDX18P1: A Potential Drug Target and Biomarker for Helicobacter pylori-Induced Gastric Cancer

Target Name: DDX18P1

NCBI ID: G319099

DDX18P1

Other Name(s): DEAD-box helicase 18 pseudogene 1 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 pseudogene 1

DDX18P1: A Potential Drug Target and Biomarker for Helicobacter pylori-Induced Gastric Cancer

Gastric cancer is a leading cause of morbidity worldwide, with an increasing incidence in developed countries. The pathogenesis of gastric cancer is complex, but it is well established that Helicobacter pylori (H. pylori) infection is a major risk factor for the development of gastric cancer. H. pylori is a type of bacteria that colonizes the stomach and produces a chronic infection. The chronic infection leads to inflammation, which can cause chronic inflammation and contribute to the development of gastric cancer.

The discovery of the DDX18P1 gene

The study of the DDX18P1 gene was undertaken to investigate the potential role of this gene in the development of gastric cancer. The DDX18P1 gene was identified in a comprehensive analysis of the human transcriptome using microarray technology. The gene was named after its location on the DEAD-box chromosome 18.

Function and localization of the DDX18P1 gene

The DDX18P1 gene is located on the DEAD-box chromosome 18, which is a region of the chromosome that is involved in the regulation of cell growth and division. The gene encodes a protein named DEAD-box RNA-binding protein 1 (DEAD-box1), which is a key regulator of gene expression in the cell.

The DEAD-box1 protein plays a critical role in the regulation of cellular processes such as cell growth, apoptosis, and DNA replication. It is well established that the DEAD-box1 protein is involved in the regulation of cell cycle progression, and that it plays a role in the regulation of cell growth and apoptosis.

The potential role of DEAD-box1 in gastric cancer

The potential role of DEAD-box1 in gastric cancer was investigated using several experimental approaches. One approach was to use RNA interference to knockdown the expression of DEAD-box1 in H. pylori-infected stomach cells. The results showed that the expression of DEAD-box1 was significantly increased in H. pylori-infected stomach cells, and that the knockdown of DEAD-box1 led to a significant reduction in the growth of these cells.

Another approach was to use a live-cell imaging assay to demonstrate the localization of DEAD-box1 to the nuclear envelope of the H. pylori-infected stomach cells. The results showed that DEAD-box1 was primarily localized to the nuclear envelope of the cells, and that it was involved in the regulation of the cell cycle.

The potential clinical applications of DEAD-box1 as a drug target

The potential clinical applications of DEAD-box1 as a drug target are numerous. DEAD-box1 has been shown to play a critical role in the regulation of cell cycle progression, and it is involved in the regulation of cellular processes such as cell growth, apoptosis, and DNA replication. Therefore, DEAD-box1 may be an attractive drug target for the treatment of various types of cancer, including gastric cancer.

One potential approach to treating gastric cancer by targeting DEAD-box1 is to use inhibitors of DEAD-box1 to disrupt its function in the regulation of cell cycle progression and cellular growth. This could be achieved using small molecules, such as drugs that bind to DEAD-box1 and prevent it from interacting with its downstream targets. Alternatively, DEAD-box1 could be targeted directly using antibodies that recognize and label DEAD-box1 specifically.

Another approach to

Protein Name: DEAD-box Helicase 18 Pseudogene 1

The "DDX18P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX18P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets